HC Wainwright Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to Strong-Buy

Key Points

• HC Wainwright upgraded TriSalus Life Sciences to “strong buy,” while other analysts’ views range from sell to buy. The stock has an overall “Moderate Buy” consensus rating and an average price target of $8.67.
• TriSalus shares opened at $4.76, with a market capitalization of approximately $293 million and a 12-month trading range of $2.20 to $7.95.
• The company reported quarterly revenue of $11.41 million, exceeding the $10.27 million consensus estimate, while adjusted earnings of a $0.16-per-share loss matched expectations. Several institutional investors also established new positions, though institutions collectively own only 2.58% of the stock.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was upgraded by investment analysts at HC Wainwright to a "strong-buy" rating in a report issued on Wednesday, Zacks reports.

TLSI has been the subject of a number of other research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen raised shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a report on Sunday, August 23rd. Finally, Lake Street Capital cut their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $8.67.

TriSalus Life Sciences Trading Up 0.6%

Shares of TriSalus Life Sciences stock opened at $4.76 on Wednesday. The stock has a market cap of $293.12 million, a P/E ratio of -3.66 and a beta of 0.44. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 12-month low of $2.20 and a 12-month high of $7.95. The business's 50 day moving average is $4.75 and its 200-day moving average is $4.33.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC bought a new position in shares of TriSalus Life Sciences during the first quarter worth approximately $20,267,000. BlackRock Inc. bought a new stake in TriSalus Life Sciences in the 2nd quarter valued at $12,099,000. Perkins Capital Management Inc. acquired a new position in TriSalus Life Sciences in the 1st quarter valued at $920,000. Nantahala Capital Management LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter valued at $4,550,000. Finally, Wasatch Advisors LP bought a new position in TriSalus Life Sciences during the 1st quarter worth $5,752,000. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.